Reprint

ABC Transporters in Human Diseases

Edited by
April 2022
494 pages
  • ISBN978-3-0365-3944-7 (Hardback)
  • ISBN978-3-0365-3943-0 (PDF)

This is a Reprint of the Special Issue ABC Transporters in Human Diseases that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Mammalian ATP-binding cassette (ABC) transporters constitute a superfamily of proteins involved in many essential cellular processes. Most of these transporters are transmembrane proteins and allow the active transport of solutes, small molecules, and lipids across biological membranes. On the one hand, some of these transporters are involved in drug resistance (also referred to as MDR or multidrug resistance), a process known to be a major brake in most anticancer treatments, and the medical challenge is thus to specifically inhibit their function. On the other hand, molecular defects in some of these ABC transporters are correlated with several rare human diseases, the most well-documented of which being cystic fibrosis, which is caused by genetic variations in ABCC7/CFTR (cystic fibrosis transmembrane conductance regulator). In the latter case, the goal is to rescue the function of the deficient transporters using various means, such as targeted pharmacotherapies and cell or gene therapy. The aim of this Special Issue, “ABC Transporters in Human Diseases”, is to present, through original articles and reviews, the state-of-the-art of our current knowledge about the role of ABC transporters in human diseases and the proposed therapeutic options based on studies ranging from cell and animal models to patients.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
ABC transporters; drug action; regulatory extension; regulatory insertion; mechanism of action; MRP1; MRP4; breast cancer; proliferation; migration; invasion; cAMP; ABCG2; ABCB1; blood-brain barrier; PET; Alzheimer’s disease; beta-amyloid; tariquidar; erlotinib; ABCG5; ABCG8; ATP-binding cassette transporter; cholesterol; polar relay; sitosterolemia; 5′ untranslated region; cis-acting elements; ABC transporters; ABCA subfamily; bioinformatics; ABC transporter; therapy response; disease-free survival; breast cancer; next-generation sequencing; competitive allele-specific PCR; P-glycoprotein; ABCB1; amyloid-beta; neuron; SK-N-SH; Alzheimer’s disease; gene therapy; AAV; PFIC; BSEP; ABCB11; bile salts; intrahepatic cholestasis; chaperones; PFIC2; BRIC; ATP-binding cassette transporter A1 (ABCA1); cholesterol homeostasis; reverse cholesterol transport; HDL-C; dyslipidemia; type 2 diabetes; microparticles; ABCG2 genotype; clinico-genetic analysis; ethnic specificity; genetic variations; precision medicine; rare variant; Roma; serum uric acid; SUA-lowering therapy; urate transporter; bile secretion; ABCB1; ABCB4; ABCB11; ABCC2; ABCG5/G8; molecular partners; phytosterol; xenosterol; cholesterol; atherosclerosis; gall stone; ABC; transporter; ABC (ATP-binding cassette) transporters; multidrug resistance; transport; trafficking; urate; mutations; polymorphisms; ABCC6; TNAP; NT5E; Pseudoxanthoma elasticum (PXE); cancer; ABC transporter; multidrug resistance; membrane protein; functional divergence; ABCG2; calcification; ABCC6; pseudoxanthoma elasticum; generalized arterial calcification of infancy; pyrophosphate; therapies; ABCA7; Alzheimer’s disease; phagocytosis; cholesterol; Aβ peptides; yeast; multidrug transporter; anticancer; antifungal resistance; ABC transporters; mechanism; ABC transporters; peroxisome; adrenoleukodystrophy; fatty acids; gout; early-onset gout; hyperuricemia; urate; uric acid; ABCG2; BCRP; ABC transporter; single nucleotide polymorphism; SNP; ABC transporter; pseudoxanthoma elasticum; homology modeling; substrate-binding site; cellular ATP efflux; mutagenesis; bile secretion; intracellular traffic; MDR3; phosphatidylcholine; RAB GTPase; P-glycoprotein; multidrug resistance; ABCB1; taxol; drug transport; ABC transporter; n/a